(Q44586206)

4 December 2017

title

Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer (English)

1 reference

4 December 2017

18

1 reference

4 December 2017

James W Denham

2

0 references

author name string

David S Lamb

1

1 reference

4 December 2017

Hedy Mameghan

3

1 reference

4 December 2017

David Joseph

4

1 reference

4 December 2017

Sandra Turner

5

1 reference

4 December 2017

John Matthews

6

1 reference

4 December 2017

Ian Franklin

7

1 reference

4 December 2017

Chris Atkinson

8

1 reference

4 December 2017

John North

9

1 reference

4 December 2017

Michael Poulsen

10

1 reference

4 December 2017

Olga Kovacev

11

1 reference

4 December 2017

Randall Robertson

12

1 reference

4 December 2017

Lynne Francis

13

1 reference

4 December 2017

David Christie

14

1 reference

4 December 2017

Nigel A Spry

15

1 reference

4 December 2017

Keen-H Tai

16

1 reference

4 December 2017

Chris Wynne

17

1 reference

4 December 2017

publication date

1 September 2003

1 reference

Radiotherapy and Oncology

4 December 2017

published in

1 reference

4 December 2017

volume

68

1 reference

4 December 2017

issue

3

1 reference

4 December 2017

page(s)

255-267

1 reference

The preservation of potency after external beam irradiation for prostate cancer

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2803%2900193-2

7 January 2021

Missing quality of life data in cancer clinical trials: serious problems and challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2803%2900193-2

7 January 2021

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2803%2900193-2

7 January 2021

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2803%2900193-2

7 January 2021

Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2803%2900193-2

7 January 2021

Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2803%2900193-2

7 January 2021

Factors influencing incidence of acute grade 2 morbidity in conformal and standard radiation treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2803%2900193-2

7 January 2021

Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: Further evidence for a significant dose effect

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2803%2900193-2

7 January 2021

A phase III double-blind randomised study of rectal sucralfate suspension in the prevention of acute radiation proctitis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2803%2900193-2

7 January 2021

Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2803%2900193-2

7 January 2021

Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2803%2900193-2

7 January 2021

Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer Program

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2803%2900193-2

7 January 2021

Hormonal cytoreduction and radiotherapy for carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2803%2900193-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2803%2900193-2

7 January 2021

Conformal static field radiation therapy treatment of early prostate cancer versus non-conformal techniques: a reduction in acute morbidity

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2803%2900193-2

7 January 2021

A quality assurance audit: phase III trial of maximal androgen deprivation in prostate cancer (TROG 96.01).

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2803%2900193-2

7 January 2021

Sexual dysfunction after radical radiation therapy for prostate cancer: a prospective evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2803%2900193-2

7 January 2021

Androgen deprivation therapy for prostate cancer results in significant loss of bone density

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2803%2900193-2

7 January 2021

Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2803%2900193-2

7 January 2021

Acute Toxicity of Conventional Radiation Therapy for High-Risk Prostate Cancer in EORTC Trial 22863

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2803%2900193-2

7 January 2021

10.1016/S0167-8140(03)00193-2

Identifiers

DOI

1 reference

4 December 2017

1 reference